Tamoxifen Metabolite Profiling by Tandem Mass Spectrometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the response to tamoxifen therapy in breast cancer patients are inadequate due to the controversy surrounding the association between CYP2D6 genotyping and individual response, and there is a need for a more effective method to quantify tamoxifen and its metabolites.
Innovation Solution
The development of methods using mass spectrometry, including tandem mass spectrometry, to quantify tamoxifen and its metabolites such as norendoxifen, endoxifen, and 4-Hydroxy Tamoxifen, allowing for the determination of their levels in patient samples, which correlates with treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CYP2D6 genotyping is used to predict response to tamoxifen, then genetic information is obtained, but the association with individual response remains controversial and unreliable
Solution Approach 1:
The patent replaces the mechanical/genetic testing approach (CYP2D6 genotyping) with a mass spectrometry-based quantitative analysis system. Instead of relying on genetic markers, the invention directly measures the actual metabolite levels (endoxifen, norendoxifen) in patient samples, substituting a more direct and reliable measurement method that correlates with treatment response.
Solution Approach 2:
The invention shifts from measuring genetic parameters (genotyping) to measuring metabolic parameters (metabolite concentrations). By changing the measured parameter from genetic information to actual metabolite levels, the system achieves more reliable prediction of treatment response, as metabolite levels directly reflect the active compounds present in the patient's system.
2Measurement precision
If mass spectrometry is used to quantify tamoxifen and metabolites, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent incorporates preliminary sample preparation steps including protein precipitation and liquid-liquid extraction before mass spectrometry analysis. These preliminary actions simplify the actual mass spectrometry measurement by pre-concentrating and purifying the analytes, reducing the complexity of the instrument analysis itself while maintaining high measurement precision.
Solution Approach 2:
The invention uses internal standards (deuterated tamoxifen and metabolites) as intermediaries in the quantification process. These internal standards are added to samples before processing and serve as reference points during mass spectrometry analysis, simplifying the quantification calculations and improving precision without requiring complex instrument adjustments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides sensitive and accurate quantification of tamoxifen metabolites, enabling a more precise prediction of treatment response and potentially improving patient outcomes by optimizing tamoxifen therapy.
Implementation Method 1
ionizing said tamoxifen and metabolites to produce one or more ions detectable by mass spectrometry
Data Source
AI summary
Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein determine the amount of N-Desmethyl Tamoxifen. In some aspects, the methods provided herein determine the amount of N-Desmethyl Tamoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein determine the amount of tamoxifen, N-Desmethyl Tamoxifen, and other tamoxifen metabolites.